Insider · CIK 0002123864
Raymond George Hill
Files at ADXN (Addex Therapeutics Ltd.). First filing -, latest -.
Raymond George Hill files SEC Form 4 as director at ADXN (Addex Therapeutics Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Raymond George Hill has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Common Stock | -1,365,532 | $0.00 | $0 | 0 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Common Stock | +1,365,532 | $0.00 | $0 | 1,365,532 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -273,107 | $0.00 | $0 | 0 | 39 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +273,107 | $0.00 | $0 | 273,107 | 39 d ago |
Questions about Raymond George Hill
Answered from the filings on this page, as of the latest one.
Is Raymond George Hill buying or selling?
Raymond George Hill has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Raymond George Hill's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Raymond George Hill has 0.
Where does Raymond George Hill file Form 4?
Raymond George Hill has filed Form 4 at ADXN (Addex Therapeutics Ltd.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.